Exelixis EXEL Net product revenues — Total revenues
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Exelixis in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Exelixis’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Exelixis's net product revenues — total revenues.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Exelixis's net product revenues — total revenues?
- Exelixis (EXEL) reported net product revenues — total revenues of $554.98M in Q1 2026.
- How has Exelixis's net product revenues — total revenues changed year-over-year?
- Exelixis's net product revenues — total revenues increased by 8.1% year-over-year, from $513.28M to $554.98M.
- What is the long-term trend for Exelixis's net product revenues — total revenues?
- Over 4 years (2021 to 2025), Exelixis's net product revenues — total revenues has grown at a 18.5% compound annual growth rate (CAGR), from $1.08B to $2.12B.
- What does net product revenues — total revenues mean?
- The total amount of money earned from selling the company's pharmaceutical products after accounting for standard industry deductions.
- How do you interpret net product revenues — total revenues?
- An increase indicates successful market penetration, strong physician adoption, or effective pricing strategies for the company's drug portfolio. A decrease may signal increased competition, loss of patent exclusivity, or challenges in patient access and reimbursement.
- How does net product revenues — total revenues compare across companies?
- This is a standard top-line metric for biopharmaceutical companies, comparable to 'Net Product Sales' reported by peers in the oncology and specialty drug sectors.